Prostate-specific membrane antigen (PSMA) gene expression predicts angiogenesis and response to tyrosine kinase inhibitors (TKIs) in patients with metastatic clear cell renal cell carcinoma (RCC), ...

No more IV drips, cancer patients on immunotherapy can now take the drug in a single injection. The National Health Service ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

Immune checkpoint inhibitor-based combinations have become the preferred first-line therapy for patients with metastatic clear cell renal cell carcinoma, but more than a third of eligible patients do ...

Researchers from The University of Texas MD Anderson Cancer Center will present promising results from clinical trials in ...

During a live event, Guru P. Sonpavde, MD discussed improvements to survival with cabozantinib plus nivolumab in metastatic ...

At AUA 2025, experts will present on novel bladder cancer therapies, advanced renal cell carcinoma comparisons, frailty in ...

Enfortumab vedotin is now available for patients who received prior platinum-containing chemotherapy and a PD-1/L1 inhibitor ...

There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were treated in the advanced setting.

The treatment of renal cell carcinoma (RCC), a malignancy that is typically chemoresistant, has drastically evolved with the introduction of vascular endothelial growth factor receptor tyrosine kinase ...

This immunomodulatory effect, combined with metabolic reprogramming, positions METTL3 as a linchpin for combination regimens integrating immunotherapy and epitranscriptomic ... This review posits that ...